Papillary craniopharyngioma
disease diseaseOn this page
Also known as craniopharyngioma, papillarycraniopharyngioma, papillary (morphologic abnormality)papillary craniopharyngioma (morphologic abnormality)papillary neoplasm of Rathke's pouchpapillary Rathke pouch neoplasmpapillary Rathke's pouch neoplasmpapillary Rathke's pouch tumorpapillary Rathke's pouch tumourpapillary tumor of Rathke's pouchpapillary tumour of Rathke's pouch
Summary
Papillary craniopharyngioma (MONDO:0002788) is a disease and 1 clinical trial. Top therapeutic interventions include cobimetinib and vemurafenib. A subtype of craniopharyngioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | papillary craniopharyngioma |
| Mondo ID | MONDO:0002788 |
| DOID | DOID:3847 |
| NCIT | C4725 |
| UMLS | C0431128 |
| MedGen | 98125 |
| GARD | 0023246 |
| Is cancer (heuristic) | no |
Also known as: craniopharyngioma, papillary · craniopharyngioma, papillary (morphologic abnormality) · papillary craniopharyngioma (morphologic abnormality) · papillary neoplasm of Rathke’s pouch · papillary Rathke pouch neoplasm · papillary Rathke’s pouch neoplasm · papillary Rathke’s pouch tumor · papillary Rathke’s pouch tumour · papillary tumor of Rathke’s pouch · papillary tumour of Rathke’s pouch
Data availability: 1 cell line.
Disease family
This is a subtype of craniopharyngioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › nervous system benign neoplasm › central nervous system organ benign neoplasm › craniopharyngioma › papillary craniopharyngioma
Related subtypes (1): adamantinous craniopharyngioma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03224767 | PHASE2 | ACTIVE_NOT_RECRUITING | Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| COBIMETINIB | 4 | 1 |
| VEMURAFENIB | 4 | 1 |
| CHEMBL3415553 | 0 | 1 |
| CHEMBL4209555 | 0 | 1 |
| CHEMBL4538425 | 0 | 1 |
| PLX-4720 | 0 | 1 |
Related Atlas pages
- Drugs: Cobimetinib, Vemurafenib